Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Palmitic Acid | HCID 985 | — |
| Reactant | Buprenorphine component OF alks-5461 | HCID 9848990 | — |
| Solvent | N-methyl-2-pyrrolidone | HCID 13387 | — |
| Product | HCID 86632414 | HCID 86632414 | — |
Reaction Steps
10 grams of the lower molecular weight copolymer described in Example 2 was dissolved in 10.1 grams of NMP to give a solution with 50% w/w copolymer and 50% w/w NMP. To this solution was added 0.2085 grams of buprenorphine base. The white powdered base was thoroughly mixed and particles crushed until a clear solution was obtained. Then 0.4170 grams of palmitic acid was added to the polymer/drug/NMP solution to complex with the buprenorphine base to form buprenorphine palmitate. The white flaky palmitic acid was crushed and thoroughly mixed until a clear solution was obtained. The resultant solution was then filtered through a 0.20 μm Teflon filter as described in Example 8 to produce a sterile solution with 1% w/w buprenorphine and 2% w/w palmitic acid. The sterile solution was stored in a glass ampule with a rubber cap until needed.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08187640B2 |
|---|
| Source dataset | uspto-grants-2012_05 |
|---|
| ORD ID | ord-ca1efc9a8ab1416e8090725cfd946076 |
|---|
| Source note | uspto-grants-2012_05 |
|---|